Natural Killer (NK) Cell Therapy for B-Cell Malignancies

NCT05379647 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma
B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: QN-019a
DRUG: Rituximab
DRUG: Cyclophosphamid
DRUG: Fludarabine
DRUG: VP-16

Sponsor

Zhejiang University

Collaborators

[object Object]